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ABSTRACT
A 1-year prospective cohort study of all episodes of Escherichia coli bacteraemia in two French university
hospitals was conducted to assess simultaneously the influence of host and bacterial determinants on the
initial severity and outcome of E. coli sepsis. Clinical data (community-acquired ⁄nosocomial infection,
immune status, underlying disease, primary source of infection, severity sepsis scoring and outcome),
phylogenetic groups (A, B1, D and B2), nine virulence factors (VFs) (papC, papGII, papGIII, sfa ⁄ foc, hlyC,
cnf1, iucC, fyuA and iroN) and the antibiotic susceptibility of isolates were investigated. All VFs except
iucC were significantly more prevalent (p <0.05) among the B2 group isolates. The non-B2 isolates were
more frequently resistant to antibiotics than were B2 isolates (p <0.05). There were significantly more B2
isolates from immunocompetent than from immunocompromised patients (p <0.05). No bacterial or
host determinants influenced the initial severity of sepsis. Multivariate analysis revealed that the
presence of papGIII, septic shock at baseline and a non-urinary tract origin of sepsis were associated
independently with a fatal outcome (p 0.04, <0.0001 and 0.04, respectively). A factorial analysis of
correspondence allowed two populations of isolates to be distinguished: those belonging to the B2 group
were associated more frequently with susceptibility to antibiotics, community-acquired infection, a
urinary tract origin and immunocompetent hosts; those belonging to the A, B1 or D groups were
associated more frequently with resistance to antibiotics, a nosocomial origin, a non-urinary tract source
and immunocompromised hosts. Although no influence of host or bacterial determinants on the initial
severity of sepsis was detected, bacterial and host determinants both influenced the outcome of E. coli
sepsis significantly.
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INTRODUCTION
Strains of Escherichia coli make up part of the
normal microflora of the gastrointestinal tract, but
are also the Gram-negative bacilli responsible
most frequently for human infections. Pathogenic
E. coli strains cause a wide variety of intestinal or
extra-intestinal infections. Extra-intestinal patho-
genic E. coli strains are responsible for urinary
tract, intra-abdominal and soft-tissue infections,
meningitis and pneumonia [1], often leading to
bacteraemia, but rarely to endocarditis [2]. Over-
all, E. coli is one of the most common bloodstream
isolates, accounting for c. 20% of all clinically
significant bloodstream isolates, and is associat-
ed with increased morbidity, mortality and
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healthcare costs [3]. In the USA, E. coli sepsis was
associated with c. 40 000 deaths, i.e., 17% of all
cases of sepsis, in 2001 [3].
Phylogenetic analyses have revealed that E. coli
can be divided into four main groups (A, B1, B2
and D) [4–6]. Extra-intestinal pathogenic E. coli
strains possess virulence factors (VFs), e.g., adhe-
sins, a capsule, cytotoxins and siderophores,
necessary to overcome host defences, to invade
host tissues, and to trigger a local inflammatory
response. Generally, highly virulent extra-intesti-
nal pathogenic E. coli strains belong to group B2,
and to a lesser extent, group D, whereas com-
mensal and less virulent strains belong to groups
A and B1 [1,7,8]. Some studies have linked
antibiotic resistance and low virulence with par-
ticular phylogenetic groups of E. coli [9–11];
indeed, non-B2 strains are commonly multidrug-
resistant, while most B2 strains appear to be
susceptible to antibiotics [10,12]. Moreover, a link
between the B2 phylogenetic group, VFs and
lethality in mice has been reported [13,14].
In humans, bacterial VFs contribute to the
occurrence of E. coli bacteraemia [15,16] and may
also influence its outcome [17]. However, pre-
dictions of initial severity and outcome based on
bacterial VFs alone are not entirely accurate, and
the consideration of host determinants, including
underlying diseases, facilitates such predictions
[15–17]. In a study of E. coli bacteraemia, host
factors, rather than phylogenetic background or
VFs, appeared to be major determinants of
outcome [18].
The question of whether E. coli VFs influence
the initial severity of sepsis in humans remains
unresolved, and no prospective study to date has
analysed the influence of phylogenetic back-
ground, VFs, antibiotic susceptibility and host
determinants on the initial severity and outcome
of E. coli bacteraemia. Accordingly, the present
study reports the findings from a large, prospect-
ive 1-year study that undertook such an analysis.
MATERIALS AND METHODS
Patients
This was a prospective study of all consecutive episodes of
E. coli bacteraemia between December 2002 and December
2003 in Necker-Enfants Malades and Avicenne University
Hospitals, Paris, France. These hospitals have 602 and 508
beds, respectively, with a large number of immunocompro-
mised patients (including children in Necker-Enfants Malades
Hospital). A standardised worksheet was used to record
clinical, epidemiological and laboratory data for each episode
in a computer database, anonymised according to French law.
Definitions
Community-acquired infections were defined as those in
which the onset of patient symptoms occurred before admis-
sion or within 48 h of admission to the hospital; hospital-
acquired infections were defined as those in which the onset of
symptoms occurred ‡48 h after admission.
Immunodeficiencies included infection with human immu-
nodeficiency virus (HIV), administration of immunosuppres-
sive therapy (corticosteroid therapy >1 mg ⁄kg ⁄day for
>30 days, immunomodulating agents and anti-neoplastic che-
motherapy) and the presence of an underlying solid tumour or
haematological malignancy. For HIV-positive patients, the
virus load, CD4+ count and anti-retroviral therapy were
recorded. Neutropenia was defined as an absolute granulocyte
count of <500 ⁄ lL at the time of blood culture sampling.
Underlying diseases also included diabetes mellitus,
defined as requiring insulin or hypoglycaemiant therapy.
Renal failure was defined as a creatinine clearance of
<30 mL ⁄min. Patients with urological abnormalities, inserted
devices, urinary tract obstruction or non-drained intra-
abdominal collections were also recorded. The level of sepsis
was graded according to the criteria of Bone et al. [19]: sepsis
was defined as a combination of infection and a systemic
inflammatory response; severe sepsis was defined as a sys-
temic response to apparent clinical infection with fever or
hypothermia (temperature >38.3C or <36.5C), tachycardia
(heart rate >90 beats ⁄min in the absence of adrenergic receptor
b-blockade) and tachypnoea (respiratory rate >20 breaths ⁄min
or a requirement for mechanical ventilation) associated with
two of the following five signs of systemic toxicity or
peripheral hypoperfusion: an increased plasma lactate con-
centration >2 mmol ⁄L; arterial hypoxaemia (partial pressure
of oxygen (PaO2) <75 torr (<10 kPa) or a PaO2 ⁄ FIO2 (fraction of
inspired oxygen) ratio <250); acute renal failure (urinary
output <0.5 mL ⁄ kg body weight ⁄h); a sudden decrease of
mental acuity; a reduction of the platelet count to <50% of the
baseline value or <100 000 platelets ⁄mm3; and septic shock
was defined as a severe sepsis with hypotension, with systolic
blood pressure <90 mmHg or a reduction of >40 mmHg from
baseline in the absence of anti-hypertensive agents despite
adequate fluid resuscitation or the use of vasopressor agents to
maintain blood pressure [19].
The primary source of bacteraemia was determined accord-
ing to the clinical presentation and by the evidence of an
identical strain cultured from blood or other body sites. Thus,
intravascular catheter infection was indicated by local signs of
inflammation and >103 CFU cultured from the removed cath-
eter tip [20]. A urinary tract infection was defined by the
presence in urine of >104 leukocytes ⁄mL and >105 CFU ⁄mL. A
lower respiratory tract infection was indicated by the presence
of a new infiltrate observed on chest radiography with no other
likely explanation, a sputum sample yielding >107 CFU ⁄mL, an
endotracheal aspirate yielding >105 CFU ⁄mL, or a broncho-
scopic protected brush yielding >103 CFU ⁄mL [21]. Infection of
other body sites was defined on the basis of clinical and
radiological criteria and a sample was obtained from the
implicated site. Outcome was defined as patients being alive
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or dead at 30 days after hospital admission. Death was attrib-
uted to E. coli sepsis if it occurred within 48 h of blood culture
sampling.
Antibiotic treatment
Initial antibiotic therapy was considered to be adequate if the
E. coli isolate was susceptible to at least one of the antibiotics
administered.
Bacterial isolates
Blood was cultured on tryptic soy agar supplemented with
sheep blood 5% v ⁄v. The first isolate from blood was
retained for the study. The API 20E system (bioMe´rieux,
Marcy l’Etoile, France) was used to identify E. coli. All
isolates were stored at )80C in brain–heart infusion broth
containing glycerol 10% v ⁄v.
Antimicrobial susceptibility testing
Antimicrobial susceptibilities were determined by the disk-
diffusion method on Mueller–Hinton agar, as recommended
by the Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise
de Microbiologie standards (http://www.sfm.asso.fr). Anti-
microbial agents tested were amoxycillin, amoxycillin–
clavulanate, cefotaxime, gentamicin, amikacin, nalidixic acid,
ofloxacin and trimethoprim–sulphamethoxazole. Multidrug-
resistant isolates were defined as those that were resistant
simultaneously to amoxycillin, ofloxacin and trimethoprim–
sulphamethoxazole.
Determination of phylogenetic groups and VFs
PCR-based methods were used to determine E. coli groups as
described previously [5]. Multiplex PCR was used to detect
genes for nine putative VFs characteristic of extra-intestinal
pathogenic E. coli (i.e., papC, P fimbriae; papGII, adhesin PapG
class II; papGIII, adhesin PapG class III; sfa ⁄ foc, S fimbriae; hlyC,
haemolysin; cnf1, cytotoxic necrotising factor; iucC, aerobactin
iron uptake system; fyuA, yersiniabactin iron uptake system;
and iroN, salmochelin iron uptake system) as described
previously [22]. The VF score was defined as the total number
of VFs detected for each isolate [23].
Statistical methods
Comparisons used the chi-square test for categorical variables
and Wilcoxon’s test for continuous variables. All tests were
two-tailed, with p <0.05 considered significant. The relation-
ship between sepsis outcome and potential explanatory var-
iables was computed using a logistic regression model.
Variables with a p value <0.1 in univariate analyses were
included in the model to determine those that were associated
independently with sepsis outcome. Conventional statistical
analyses were performed using the SAS v.9.1 software package
(SAS Institute, Cary, NC, USA).
Concurrently, a factorial analysis of correspondence (FAC)
[24] was performed to identify particular subgroups of host or
bacterial determinants and to illustrate their potential impact on
sepsis severity or outcome. SPAD.N software (Cisia, Saint
Mande´, France) was used for FAC, with a two-way table
including 161 rows, one for each E. coli isolate, and three
columns corresponding to the 17 clinical variables retained for
the study, i.e., the four phylogenetic groups, the nine VFs and the
three major antibiotics tested. For each column, each isolate was
given a binary code: present = 1; absent = 0. The FAC used a
covariance matrix based on chi-square distances. The compu-
tation determined a plane that was defined by two principal axes
of the analysis: the first axis, F1, accounting for most of the
variance, and the second axis, F2—orthogonal to F1—account-
ing for the largest part of the variance not accounted for by F1.
The variables could be positioned in the F1 ⁄ F2 plane according
to their coordinates for each of these factors. The positioning
described the relationship between variables. If two variables
were close to each other in the plane, they were considered to be
strongly associated, and if they were distant from each other in
the plane, the variables were not associated.
RESULTS
Description of episodes
In total, 161 episodes of E. coli bacteraemia (inclu-
ding 14 in children) were studied in the Necker-
Enfants Malades (n = 75) and Avicenne (n = 86)
hospitals. The primary source of bacteraemia was
suspected in 94 cases and confirmed microbio-
logically in 78 cases; the latter sources comprised
urinary tract (n = 62), gastrointestinal tract
(n = 7), respiratory tract (n = 3), early-onset neo-
natal infection (n = 3), skin (n = 2) and a central
venous catheter (n = 1).
Bacterial characteristics
Antibiotic susceptibility. The E. coli isolates exhib-
ited a high rate of resistance to amoxycillin
(59.6%), amoxycillin–clavulanate (46.6%), trim-
ethoprim–sulphamethoxazole (38.5%) and, to a
lesser extent, ofloxacin (19.3%) (Table 1). Of the
161 E. coli isolates, 4.3% were resistant to third-
generation cephalosporins. Only 6.2% of the
isolates were resistant to gentamicin and 1.9%
were resistant to amikacin (data not shown).
Phylogenetic groups. B2 group isolates were pre-
dominant (49.7%), followed by group D (23.0%),
group A (21.1%) and group B1 (6.2%) isolates. In
addition, non-B2 isolates were more frequently
multidrug-resistant than were B2 isolates
(p <0.001) (Table 1).
Virulence profiles. The fyuA and iucC genes, present
in 77.6% and 65.8% of the isolates, respectively,
were the most prevalent (Table 1). With the
exception of iucC, all VFs were significantly more
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prevalent among B2 group isolates than among
non-B2 isolates (p <0.001). B2 group isolates had a
median VF score per isolate of 6, which was
significantly higher than the score of 2 for non-B2
isolates (p <0.001).
Primary source of bacteraemia. Overall, 50% of the
B2 group isolates were associated with a urinary
tract origin, compared with 32.1% of non-B2
isolates (p 0.02) (data not shown). The VFs papC,
papGII and fyuA were more prevalent among
urinary tract E. coli isolates than among isolates
with another origin (p <0.05) (data not shown).
Host determinants
The mean age of the 161 patients was 58 years
(range 6 days - 95 years); 52%were male and 51%
were aged >65 years. In total, 38.5% of the cases
had infections that were nosocomial in origin, 36%
were immunocompromised, and 19.9% had a
haematological malignancy and ⁄ or a solid tumour
(18.6%) and ⁄ or HIV infection (3.1%). The virus
load of the five HIV-infected patients varied from
60 to 600 000 copies ⁄mL, with CD4+ T-lymphocyte
counts of 20–383 ⁄lL. One HIV-infected patient was
untreated, three were non-adherent to anti-retro-
viral agent regimens, and two others received
stavudine–lamivudine–lopinavir and abacavir–
tenofovir–lamivudine, respectively. Diabetes mell-
itus and renal failure were each reported for 20.5%
of the patients. Scoring the severity of sepsis
revealed that 81.1% of the patients had sepsis,
7.5% had severe sepsis, and 11.1% were in septic
shock. Thirty (18.6%) patients were considered to
have received inadequate initial antibiotic therapy
and 18 patients died; of these, 16 deaths were
attributed to E. coli sepsis.
The age and gender of the patients were not
related to the phylogenetic E. coli group (data not
shown). However, there was a relationship
between gender and the source of infection, with
a significantly higher percentage of females having
urosepsis (54.5% vs. 28.6%, p <0.001), whereas the
digestive tract was a more common source of
infection in males (16.7% vs. 3.9%, p 0.008).
There were significantly more E. coli isolates
belonging to the B2 group from immunocompe-
tent patients than from immunocompromised
patients (p 0.04) (Table 2). Isolates that were
resistant to ofloxacin were found in a higher
percentage of immunocompromised patients than
of immunocompetent patients (28.8% and 13.7%,
respectively, p 0.02). There was a trend towards a
higher frequency of most VFs in immunocompe-
tent hosts (Table 2). Group D E. coli isolates were
Table 1. Antibiotic susceptibilities and virulence factors (VFs), grouped according to phylogenetic group, of 161 Escherichia















Amoxycillin 22 (64.7) 7 (70.0) 26 (70.0) 55 (67.9) 41 (51.3) <0.05
AC 17 (50.0) 6 (60.0) 20 (54.1) 43 (53.1) 32 (40.0) –c
Nalidixic acid 12 (35.3) 4 (40.0) 10 (27.0) 26 (32.1) 7 (8.8) <0.001
Ofloxacin 11 (32.4) 4 (40.0) 9 (24.3) 24 (29.6) 7 (8.8) <0.001
TMP ⁄ SXT 19 (55.9) 6 (60.0) 19 (51.4) 44 (54.3) 18 (22.5) <0.001
MR 11 (32.4) 4 (40.0) 6 (16.2) 21 (25.9) 4 (5.0) <0.001
VFs
papC 9 (26.5) 0 (0) 10 (27.0) 19 (23.5) 60 (75.0) <0.001
papGII 2 (5.9) 0 (0) 9 (24.3) 11 (13.6) 36 (45.0) <0.001
papGIII 0 (0) 0 (0) 0 (0) 0 (0) 27 (33.8) <0.001
sfa ⁄ foc 1 (2.9) 0 (0) 0 (0) 1 (1.2) 46 (57.5) <0.001
hlyC 2 (5.9) 0 (0) 1 (2.7) 3 (3.7) 48 (60.0) <0.001
cnf1 1 (2.9) 0 (0) 0 (0) 1 (1.2) 47 (58.8) <0.001
iucC 23 (67.6) 3 (30.0) 28 (75.7) 53 (65.4) 52 (65.0) –
iroN 15 (44.1) 5 (50.0) 10 (27.0) 30 (37.0) 63 (78.8) <0.001
fyuA 19 (55.9) 5 (50.0) 21 (56.8) 44 (54.3) 80 (100.0) <0.001
VF scoreb 2 (1–3) 1.5 (0–2) 2 (1–3) 2 (1–3) 6 (5–7) <0.0001
Data are displayed as number (%) of isolates.
AC, amoxycillin–clavulanate; TMP ⁄ SXT, trimethoprim–sulphamethoxazole; MR, amoxycillin + ofloxacin + trimethoprim–sulphamethoxazole; papC, P fimbriae; papGII,
adhesin PapG class II; papGIII, adhesin PapG class III; sfa ⁄ foc, S fimbriae; hlyC, haemolysin; cnf1, cytotoxic necrotising factor; iucC, iron uptake system (IUS) aerobactin; fyuA,
IUS yersiniabactin; iroN, IUS salmochelin.
aB2 vs. non-B2 group isolates.
bMedian (inter-quartile range) number of virulence factors per isolate.
cnot statistically significant.
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more prevalent in nosocomial infections than in
community-acquired infections (32.3% and
17.2%, respectively, p 0.03). The papC and papGII
genes were associated significantly with commu-
nity-acquired bacteraemia (p 0.006 and p 0.03,
respectively) (data not shown).
Determinants of the initial severity of sepsis
None of the host and bacterial determinants
studied was associated with the initial severity
of E. coli sepsis (Table 3). However, there was a
relationship between gender and the severity of
infection; initial severe infection originating from
the digestive tract was associated with male
gender (p 0.05), while the urinary tract was the
most frequent source of infection in 53.9% of
women with initial severe sepsis (data not
shown). A non-urinary source was associated
more frequently with severe sepsis and septic
shock (Table 3).
Determinants of sepsis outcome
Bacterial and host determinants were not asso-
ciated with a fatal outcome, with the exception
of papGIII (p 0.04), but septic shock was associ-
ated significantly with fatal outcome (p <0.0001)
(Table 4). Determinants found to be associated
significantly with fatal outcome after univariate
analysis were septic shock and the papGIII gene
(p <0.0001 and p 0.04, respectively) (Table 4).
Multivariate analysis revealed that determinants
associated significantly with mortality were sep-
tic shock (p <0.0001), a non-urinary tract origin
(p 0.04) and the papGIII gene (p 0.04).
E. coli sepsis leading to death occurred in a
higher percentage of males than of females
(14.1% vs. 6.5%, respectively). Moreover, a urin-
ary source was associated more frequently with a
favourable outcome (p 0.05) (Table 4). Inappro-
priate antibiotic treatment was not associated
with a higher rate of mortality when compared
with appropriate treatment (18.8% and 81.2%,
respectively) (data not shown).
Factorial analysis of correspondence
FAC revealed two distinct groups of bacteraemic
E. coli isolates (Fig. 1). The first group, projected
on the negative value of the first axis (factor 1),
included isolates responsible for community-
acquired episodes, those originating from the
urinary tract, those from immunocompetent
patients, and those belonging to the B2 phylo-
genetic group that exhibited a high number of
VFs and a low frequency of antibiotic resistance.
The second group, projected on the positive value
of the first axis (factor 1), included isolates
responsible for nosocomial episodes, those ori-
ginating from sources other than the urinary tract,
those occurring in immunocompromised hosts,
Table 2. Microbiological character-
istics of Escherichia coli isolates,




host (n = 59)
Immunocompetent
host (n = 102) p value
Phylogenetic
group
A 34 14 (23.7) 20 (19.6) –a
B1 10 4 (6.8) 6 (5.9) –
B2 80 23 (39.0) 57 (55.9) <0.04
D 37 18 (30.5) 19 (18.6) –
Non-B2 (A, B1, D) 81 36 (61.0) 45 (44.1) <0.05
Resistance to
antibiotics
Amoxycillin 96 41 (69.5) 55 (53.9) 0.05
Ofloxacin 31 17 (28.8) 14 (13.7) 0.02
TMP ⁄ SXT 62 28 (47.5) 34 (33.3) –
Virulence
factors
papC 79 23 (39.0) 56 (54.9) –
papGII 47 15 (25.4) 32 (31.4) –
papGIII 27 6 (10.2) 21 (20.6) –
sfa ⁄ foc 47 15 (25.4) 32 (31.4) –
hlyC 51 17 (28.8) 34 (33.3) –
cnf1 48 15 (25.4) 33 (32.4) –
iucC 106 41 (69.5) 65 (63.7) –
iroN 93 29 (49.1) 64 (62.7) –
fyuA 125 41 (69.5) 84 (82.4) –
Data are displayed as number (%) of isolates.
TMP ⁄ SXT, trimethoprim–sulphamethoxazole; papC, P fimbriae; papGII, adhesin PapG class II; papGIII, adhesin
PapG class III; sfa ⁄ foc, S fimbriae; hlyC, haemolysin; cnf1, cytotoxic necrotising factor; iucC, iron uptake system (IUS)
aerobactin; fyuA, IUS yersiniabactin; iroN, IUS salmochelin.
aNot statistically significant.
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and those belonging to the A, B1 or D phylo-
genetic groups that exhibited a low number of
VFs and a high frequency of antibiotic resistance.
Septic shock and a fatal outcome of sepsis were
projected on the negative values of the second
axis (factor 2), and thus appeared to be unrelated
to variables distinguished by host and bacterial
characteristics (factor 1), as factor 2 is independ-
ent of (orthogonal) factor 1.
DISCUSSION
The 161 bacteraemic E. coli isolates belonged
predominantly (49.7%) to phylogenetic group
B2. However, this overall percentage was lower
than that reported in previous studies, whereas
the prevalence of phylogenetic groups A and D
was higher [7,25–27]. The frequency of antimicro-
bial resistance in clinical E. coli isolates from
humans has increased over the past two decades
[28], and low intrinsic bacterial virulence corre-
lates with antibiotic resistance [9–11,29]. The
present study found a significant association
between a high rate of resistance to commonly
used antimicrobial agents, including ofloxacin
and trimethoprim–sulphamethoxazole, and less
Table 3. Influence of host and bacterial determinants on






(n = 30) p value
Host determinants
Age ‡65 years 64 (48.9) 15 (50.0) –d
Male gender 67 (51.1) 17 (56.7) –
Diabetes mellitus 29 (22.1) 4 (13.3) –
Any urological abnormalities 28 (21.4) 11 (36.7) –
Neoplasia 26 (19.8) 4 (13.3) –
Haematological malignancy 29 (22.1) 3 (10.0) –
HIV infection 3 (2.3) 2 (6.7) –
Renal failure 23 (17.6) 4 (13.3) –
Immune status
Immunocompetent 82 (62.6) 20 (66.7) –
Immunocompromised 49 (37.4) 10 (33.3) –
Origin of infection
Community-acquired 77 (58.8) 22 (73.3) –
Nosocomial 54 (41.2) 8 (26.7) –
Source of bacteraemiaa
Urinary tract 56 (42.7) 10 (33.3) –
Digestive tractb 12 (9.2) 5 (16.7) –
Otherc 7 (5.3) 4 (13.3) –
Bacterial determinants
Phylogenetic group
A1 30 (22.9) 3 (10.0) –
B1 7 (5.3) 3 (10.0) –
B2 66 (50.4) 14 (46.7) –
D 28 (21.4) 9 (30.0) –
Resistance to antibiotics
Amoxycillin 77 (58.8) 19 (63.3) –
Ofloxacin 27 (20.6) 4 (13.3) –
TMP ⁄ SXT 49 (37.4) 13 (43.3) –
Virulence factors
papC 64 (48.9) 15 (50.0) –
papGII 38 (29.0) 9 (30.0) –
papGIII 20 (15.3) 7 (23.3) –
sfa ⁄ foc 38 (29.0) 9 (30.0) –
hlyC 39 (29.8) 12 (40.0) –
cnf1 36 (27.5) 12 (40.0) –
iucC 84 (64.1) 22 (73.3) –
iroN 71 (54.2) 22 (73.3) –
fyuA 101 (77.1) 23 (76.7) –
Data are displayed as number (%) of isolates.
TMP ⁄ SXT, trimethoprim–sulphamethoxazole; papC, P fimbriae; papGII, PapG class
II adhesin; papGIII, PapG class III adhesin; sfa ⁄ foc, S fimbriae; hlyC, haemolysin; cnf1,
cytotoxic necrotising factor; iucC, iron uptake system (IUS) aerobactin; fyuA, IUS
yersiniabactin; iroN, IUS salmochelin; HIV, human immunodeficiency virus.
aThe primary source of bacteraemia was suspected in 94 cases and confirmed
microbiologically in 78 cases.
bIncluding patients with non-drained intra-abdominal abscesses.
cOthers: respiratory tract (n = 4), gastric aspirate in neonates (n = 3), skin (n = 3),
and a central venous catheter (n = 1).
dNot statistically significant.
Table 4. Univariate analysis of host and bacterial deter-




(n = 16) p value
Host determinants
Age ‡65 years 67 (48.2) 8 (50.0) –e
Male gender 67 (48.2) 11 (68.8) –
Diabetes mellitus 28 (20.1) 2 (12.5) –
Any urological abnormalities 35 (25.0) 4 (25.0) –
Neoplasia 24 (17.3) 4 (25.0) –
Haematological malignancy 27 (19.4) 2 (12.5) –
HIV infection 3 (2.2) 2 (12.5) –
Renal failure 28 (20.1) 4 (25.0) –
Immune status
Immunocompetent 89 (64.0) 10 (62.5) –
Immunocompromised 50 (36.0) 6 (37.5) –
Origin of infection
Community 86 (61.9) 10 (62.5) –
Nosocomial 53 (38.1) 6 (37.5) –
Suspected source of bacteraemiaa
Urinary tract 62 (44.6) 3 (18.8) 0.05
Digestive tractb 12 (8.6) 3 (18.8) –
Otherc 9 (6.5) 2 (12.5) –
Severity sepsis scoring
Sepsis 124 (89.2) 2 (12.5) –
Severe sepsis 11 (7.9) 1 (6.3) –
Septic shock 4 (2.9) 13 (81.3) <0.00001
Bacterial determinants
Phylogenetic group
A 32 (23.0) 1 (6.3) –
B1 8 (5.8) 1 (6.3) –
B2 70 (50.4) 9 (56.3) –
D 29 (20.9) 5 (31.3) –
Resistance to antibiotics
Amoxycillin 81 (58.3) 10 (62.3) –
Ofloxacin 27 (19.4) 2 (12.5) –
TMP ⁄ SXT 55 (39.6) 5 (31.3) –
Virulence factors
papC 67 (48.2) 10 (62.3) –
papGII 42 (30.2) 4 (25.0) –
papGIII 21 (15.1) 6 (37.5) 0.04
sfa ⁄ foc 42 (30.2) 5 (31.3) –
hlyC 44 (31.7) 7 (43.8) –
cnf1 41 (29.5) 7 (43.8) –
iucC 90 (64.7) 11 (68.8) –
iroN 78 (56.1) 12 (87.5) –
fyuA 108 (77.7) 14 (87.5) –
Data are displayed as number (%) of isolates.
TMP ⁄ SXT, trimethoprim–sulphamethoxazole; papC, P fimbriae; papGII, PapG class
II adhesin; papGIII, PapG class III adhesin; sfa ⁄ foc, S fimbriae; hlyC, haemolysin; cnf1,
cytotoxic necrotising factor; iucC, iron uptake system (IUS) aerobactin; fyuA, IUS
yersiniabactin; iroN, IUS salmochelin; HIV, human immunodeficiency virus.
aThe primary source of bacteraemia was suspected in 94 cases and confirmed
microbiologically in 78 cases.
bIncluding patients with non-drained intra-abdominal abscesses.
cOthers: respiratory tract (n = 4), neonatal gastric aspirate (n = 3), skin (n = 3) and a
central venous catheter (n = 1).
dAttributed to E. coli sepsis.
eNot statistically significant.
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virulent non-B2 isolates, which were more
exposed to pressure from antibiotic selection
within the intestinal tract. In contrast, as docu-
mented previously, B2 isolates had a higher
intrinsic level of virulence than non-B2 isolates.
Indeed, all tested VFs, except iucC, were signifi-
cantly more prevalent among group B2 isolates
than among all the non-B2 groups combined.
Mobility of the aerobactin gene complex between
plasmids and the chromosome, and among bac-
terial species by means of conjugative plasmids,
might explain the wide distribution of this iron
assimilation system among the B2 and non-B2
isolates [30]. The high prevalence of fyuA ob-
served in isolates from both immunocompro-
mised and immunocompetent hosts indicates
that this VF might be a useful target for thera-
peutic intervention [7].
It has been reported previously that the distri-
bution of bacterial characteristics depends on the
primary source of E. coli bacteraemia [15,16,26].
The present study found that a urinary tract
source was associated significantly with B2 iso-
lates, thereby confirming the results of previous
studies [26], and also with the presence of papC
and papGII, with the latter known to be associated
with the pathogenesis of E. coli urosepsis
[15,16,26,31]. All tested VFs, except iucC, were
significantly more prevalent among isolates from
immunocompetent patients, and papC and papGII
were associated with community-acquired iso-
lates, thereby indicating that the products of these
genes help bacteria to overcome host defences, so
that they are less necessary in immunocompro-
mised patients with nosocomial E. coli bacterae-
mia [26,32–34].
No previous study has investigated associa-
tions between host and bacterial determinants
and the initial severity and outcome of E. coli
sepsis in humans. The present study failed to
associate any particular bacterial determinant
with the initial severity of sepsis. It has been
suggested that host determinants override bac-
terial VFs in determining the course of E. coli
sepsis [17]. However, immunocompromised
hosts experienced a severity of sepsis compar-
able to immunocompetent patients in the present
study. Although some studies have reported that
the source of infection could be associated with
the initial severity of sepsis [17,26,35], there was
only a tendency towards significance in the
present study.
Bacterial determinants were not associated
with an increased fatal outcome, with the excep-
tion of the papGIII gene. This VF occurs
more frequently in E. coli isolates associated with
Fig. 1. Projections of 34 bacterial variables (m), including the virulence factors (n) and the clinical variables (n),
characterised in the 161 Escherichia coli isolates, on the plane F1 ⁄F2 computed from the factorial analysis of correspondence.
The virulence factors are: papC, P fimbriae; papGII, PapG class II adhesin; papGIII, PapG class III adhesin; sfa ⁄ foc, S fimbriae;
hlyC, haemolysin; cnf1, cytotoxic necrotising factor; iucC, iron uptake system (IUS) aerobactin; fyuA, IUS yersiniabactin; and
iroN, IUS salmochelin. The clinical variables are labelled as follows: fema, female; male, male; <65, age <65 years; >65, age
>65 years; UTO, urinary tract origin; DTO, digestive tract origin; OTO, other tract origin; UNO, unknown origin; sepsis,
severe sepsis, septic shock; DEA, death; DAS, death attributed to sepsis; HM, haematological malignancy; DIA, diabetes;
NEO, neoplasia; RFA, renal failure; ICO, immunocompetent host; ICH, immunocompromised host; noso, nosocomial
infection; com, community-acquired infection; SXT, trimethoprim-sulphamethoxazole; AMX, amoxycillin; OFX, ofloxacin.
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prostatitis [36]. However, in the six cases in the
present study in which papGIII was associated
with a fatal outcome, there was no urosepsis.
A correlation between the administration of
inadequate antibiotic treatment for bloodstream
infections and hospital mortality has been repor-
ted previously [37,38]. However, of the 30 patients
with initial severe sepsis and septic shock in the
present study, only four (13.3%) received inad-
equate antibiotic treatment. A previous study
reported increased mortality in critically-ill pa-
tients with nosocomial vs. community-acquired
E. coli bacteraemia [39]. However, the present
data showed that the eight (26.7%) patients with
severe sepsis and septic shock resulting from
nosocomial infections had a similar mortality rate
to that of patients with severe community-
acquired bacteraemia.
Finally, FAC was able to delineate two groups
of E. coli isolates. Isolates belonging to phylo-
genetic group B2 were associated more frequently
with VF genes, susceptibility to commonly pre-
scribed antibiotics, community-acquired infection,
a urinary tract origin and an immunocompetent
host. In contrast, isolates belonging to groups A,
B1 and D were associated more frequently with
antimicrobial resistance, nosocomial infection, a
non-urinary tract origin and an immunocompro-
mised host. However, these two groups were not
associated with the severity or the outcome of
sepsis.
In conclusion, although this study failed to
provide evidence for any influence of host or
bacterial determinants on the initial severity of
sepsis, the presence of septic shock and the
papGIII gene influenced the outcome of E. coli
sepsis significantly. Further studies of a larger
number of patients, incorporating other approa-
ches such as macroarrays and studies of host
immune defects, are necessary to assess the
influence of these determinants on the initial
severity and outcome of E. coli sepsis.
REFERENCES
1. Russo TA, Johnson JR. Proposal for a new inclusive
designation for extraintestinal pathogenic isolates of
Escherichia coli: ExPEC. J Infect Dis 2000; 181: 1753–1754.
2. Micol R, Lortholary O, Jaureguy F et al. Escherichia coli
native valve endocarditis. Clin Microbiol Infect 2006; 12:
401–403.
3. Russo TA, Johnson JR. Medical and economic impact of
extraintestinal infections due to Escherichia coli: focus on an
increasingly important endemic problem. Microb Infect
2003; 5: 449–456.
4. Herzer PJ, Inouye S, Inouye M, Whittam TS. Phylogenetic
distribution of branched RNA-linked multicopy single-
stranded DNA among natural isolates of Escherichia coli.
J Bacteriol 1990; 172: 6175–6181.
5. Clermont O, Bonacorsi S, Bingen E. Rapid and simple
determination of the Escherichia coli phylogenetic group.
Appl Environ Microbiol 2000; 66: 4555–4558.
6. Selander RK, Caugant DA, Ochman H, Musser JM, Gil-
mour MN, Whittam TS. Methods of multilocus enzyme
electrophoresis for bacterial population genetics and sys-
tematics. Appl Environ Microbiol 1986; 51: 873–884.
7. Johnson JR, Stell AL. Extended virulence genotypes of
Escherichia coli strains from patients with urosepsis in
relation to phylogeny and host compromise. J Infect Dis
2000; 181: 261–272.
8. Johnson JR, Russo TA. Extraintestinal pathogenic Escheri-
chia coli: ‘the other bad E coli’. J Lab Clin Med 2002; 139:
155–162.
9. Johnson JR, Kuskowski MA, Owens K, Gajewski A,
Winokur PL. Phylogenetic origin and virulence genotype
in relation to resistance to fluoroquinolones and ⁄ or
extended-spectrum cephalosporins and cephamycins
among Escherichia coli isolates from animals and humans.
J Infect Dis 2003; 188: 759–768.
10. Johnson JR, Kuskowski MA, Gajewski A, Sahm DF,
Karlowsky JA. Virulence characteristics and phylogenetic
background of multidrug-resistant and antimicrobial-sus-
ceptible clinical isolates of Escherichia coli from across the
United States, 2000–2001. J Infect Dis 2004; 190: 1739–1744.
11. Sannes MR, Kuskowski MA, Johnson JR. Antimicrobial
resistance of Escherichia coli strains isolated from urine of
women with cystitis or pyelonephritis and feces of dogs
and healthy humans. J Am Vet Med Assoc 2004; 225:
368–373.
12. Horcajada JP, Soto S, Gajewski A et al. Quinolone-resistant
uropathogenic Escherichia coli strains from phylogenetic
group B2 have fewer virulence factors than their suscept-
ible counterparts. J Clin Microbiol 2005; 43: 2962–2964.
13. Picard B, Garcia JS, Gouriou S et al. The link between
phylogeny and virulence in Escherichia coli extraintestinal
infection. Infect Immun 1999; 67: 546–553.
14. Johnson JR, Clermont O, Menard M, Kuskowski MA,
Picard B, Denamur E. Experimental mouse lethality of
Escherichia coli isolates, in relation to accessory traits,
phylogenetic group, and ecological source. J Infect Dis
2006; 194: 1141–1150.
15. Wang MC, Tseng CC, Chen CY, Wu JJ, Huang JJ. The role
of bacterial virulence and host factors in patients with
Escherichia coli bacteremia who have acute cholangitis or
upper urinary tract infection. Clin Infect Dis 2002; 35:
1161–1166.
16. Tseng CC, Wu JJ, Liu HL, Sung JM, Huang JJ. Roles of host
and bacterial virulence factors in the development of up-
per urinary tract infection caused by Escherichia coli. Am J
Kidney Dis 2002; 39: 744–752.
17. Hekker TA, Groeneveld AB, Simoons-Smit AM, de Man P,
Connell H, MacLaren DM. Role of bacterial virulence factors
and host factors in the outcome of Escherichia coli bacterae-
mia. Eur J Clin Microbiol Infect Dis 2000; 19: 312–316.
18. Martinez JA, Soto S, Fabrega A et al. Relationship of phy-
logenetic background, biofilm production, and time to
Jaure´guy et al. Escherichia coli sepsis 861
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 854–862
detection of growth in blood culture vials with clinical
variables and prognosis associated with Escherichia coli
bacteremia. J Clin Microbiol 2006; 44: 1468–1474.
19. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis
and organ failure. Crit Care Med 1992; 20: 724–726.
20. O’Grady NP, Alexander M, Dellinger EP et al. Guidelines
for the prevention of intravascular catheter-related infec-
tions. Centers for Disease Control and Prevention. MMWR
Recomm Rep 2002; 51: 1–29.
21. Anonymous. Guidelines for the management of adults
with hospital-acquired, ventilator-associated, and health-
care-associated pneumonia. Am J Respir Crit Care Med
2005; 171: 388–416.
22. Bonacorsi S, Houdouin V, Mariani-Kurkdjian P, Mahjoub-
Messai F, Bingen E. Comparative prevalence of virulence
factors in Escherichia coli causing urinary tract infection in
male infants with and without bacteremia. J Clin Microbiol
2006; 44: 1156–1158.
23. Johnson JR, O’Bryan TT, Kuskowski M, Maslow JN.
Ongoing horizontal and vertical transmission of virulence
genes and papA alleles among Escherichia coli blood isolates
from patients with diverse-source bacteremia. Infect
Immun 2001; 69: 5363–5374.
24. Greenacre M. Correspondence analysis in medical
research. Stat Methods Med Res 1992; 1: 97–117.
25. Johnson JR, Goullet PH, Picard B, Moseley SL, Roberts PL,
Stamm WE. Association of carboxylesterase B electropho-
retic pattern with presence and expression of urovirulence
factor determinants and antimicrobial resistance among
strains of Escherichia coli causing urosepsis. Infect Immun
1991; 59: 2311–2315.
26. Johnson JR, Kuskowski MA, O’Bryan TT, Maslow JN.
Epidemiological correlates of virulence genotype and
phylogenetic background among Escherichia coli blood
isolates from adults with diverse-source bacteremia.
J Infect Dis 2002; 185: 1439–1447.
27. Sannes MR, Kuskowski MA, Owens K, Gajewski A,
Johnson JR. Virulence factor profiles and phylogenetic
background of Escherichia coli isolates from veterans with
bacteremia and uninfected control subjects. J Infect Dis
2004; 190: 2121–2128.
28. Johnson JR, Manges AR, O’Bryan TT, Riley LW. A dis-
seminated multidrug-resistant clonal group of uropatho-
genic Escherichia coli in pyelonephritis. Lancet 2002; 359:
2249–2251.
29. Moreno E, Prats G, Sabate M, Perez T, Johnson JR, Andreu
A. Quinolone, fluoroquinolone and trimethoprim ⁄ sulf-
amethoxazole resistance in relation to virulence determi-
nants and phylogenetic background among uropathogenic
Escherichia coli. J Antimicrob Chemother 2006; 57: 204–211.
30. Bindereif A, Neilands JB. Aerobactin genes in clinical
isolates of Escherichia coli. J Bacteriol 1985; 161: 727–735.
31. Moreno E, Planells I, Prats G, Planes AM, Moreno G,
Andreu A. Comparative study of Escherichia coli virulence
determinants in strains causing urinary tract bacteremia
versus strains causing pyelonephritis and other sources of
bacteremia. Diagn Microbiol Infect Dis 2005; 53: 93–99.
32. Johnson JR, Moseley SL, Roberts PL, Stamm WE. Aerob-
actin and other virulence factor genes among strains of
Escherichia coli causing urosepsis: association with patient
characteristics. Infect Immun 1988; 56: 405–412.
33. Maslow JN, Mulligan ME, Adams KS, Justis JC, Arbeit RD.
Bacterial adhesins and host factors: role in the develop-
ment and outcome of Escherichia coli bacteremia. Clin Infect
Dis 1993; 17: 89–97.
34. Karkkainen UM, Ikaheimo R, Katila ML, Sivonen A,
Siitonen A. Low virulence of Escherichia coli strains causing
urinary tract infection in renal disease patients. Eur J Clin
Microbiol Infect Dis 2000; 19: 254–259.
35. Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA.
Community-acquired bloodstream infection in critically ill
adult patients: impact of shock and inappropriate antibi-
otic therapy on survival. Chest 2003; 123: 1615–1624.
36. Ruiz J, Simon K, Horcajada JP et al. Differences in viru-
lence factors among clinical isolates of Escherichia coli
causing cystitis and pyelonephritis in women and prost-
atitis in men. J Clin Microbiol 2002; 40: 4445–4449.
37. Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R,
Nogueira JM. The influence of inadequate empirical anti-
microbial treatment on patients with bloodstream infec-
tions in a intensive care unit. Clin Microbiol Infect 2003; 9:
412–418.
38. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH.
The influence of inadequate antimicrobial treatment of
bloodstream infections on patient outcomes in the ICU
setting. Chest 2000; 118: 146–155.
39. Blot S, Vandewoude K, Hoste E et al. Absence of excess
mortality in critically ill patients with nosocomial Escheri-
chia coli bacteremia. Infect Control Hosp Epidemiol 2003; 24:
912–915.
862 Clinical Microbiology and Infection, Volume 13 Number 9, September 2007
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 854–862
